CHRS vs. AUTL, VALN, XERS, MAZE, TECX, MGTX, MLYS, TRDA, RNAC, and HUMA
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Autolus Therapeutics (AUTL), Valneva (VALN), Xeris Biopharma (XERS), Maze Therapeutics (MAZE), Tectonic Therapeutic (TECX), MeiraGTx (MGTX), Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), Cartesian Therapeutics (RNAC), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry.
Coherus BioSciences vs.
Autolus Therapeutics (NASDAQ:AUTL) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Autolus Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Coherus BioSciences received 221 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 67.96% of users gave Autolus Therapeutics an outperform vote while only 65.31% of users gave Coherus BioSciences an outperform vote.
72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Autolus Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Autolus Therapeutics' return on equity.
Autolus Therapeutics currently has a consensus price target of $10.40, suggesting a potential upside of 433.33%. Coherus BioSciences has a consensus price target of $5.38, suggesting a potential upside of 402.34%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Coherus BioSciences.
In the previous week, Autolus Therapeutics had 2 more articles in the media than Coherus BioSciences. MarketBeat recorded 2 mentions for Autolus Therapeutics and 0 mentions for Coherus BioSciences. Autolus Therapeutics' average media sentiment score of 1.52 beat Coherus BioSciences' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media.
Autolus Therapeutics has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Autolus Therapeutics beats Coherus BioSciences on 13 of the 18 factors compared between the two stocks.
Get Coherus BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coherus BioSciences Competitors List
Related Companies and Tools
This page (NASDAQ:CHRS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CHRS Stock Alerts